Adverse Events with Biomedicines

Part I. General Aspects

1. Introduction
Giuseppe Tridente

2. Adverse Drug Events to Biomedicines
Giuseppe Tridente

3. Systemic Syndromes with Biomedicines
Giuseppe Tridente

Part II. Monoclonal Antibodies

4. Monoclonal Antibodies
Giuseppe Tridente

5. Abciximab
Giuseppe Tridente

6. Adalimumab
Giuseppe Tridente

7. Alemtuzumab
Giuseppe Tridente

8. Basiliximab
Giuseppe Tridente

9. Belimumab
Giuseppe Tridente

10. Bevacizumab
Giuseppe Tridente

11. Brentuximab
Giuseppe Tridente

12. Canakinumab
Giuseppe Tridente

13. Catumaxomab
Giuseppe Tridente

14. Certolizumab
Giuseppe Tridente

15. Cetuximab
Giuseppe Tridente

16. Daclizumab
Giuseppe Tridente

17. Denosumab
Giuseppe Tridente

18. Eculizumab
Giuseppe Tridente

19. Edrecolomab
Giuseppe Tridente

20. Efalizumab
Giuseppe Tridente

21. Gemtuzumab
Giuseppe Tridente

22. Golimumab
Giuseppe Tridente

23. Ibritumomab
Giuseppe Tridente

24. Infliximab
Giuseppe Tridente

25. Ipilimumab
Giuseppe Tridente

26. Muromonab
Giuseppe Tridente

27. Natalizumab
Giuseppe Tridente

28. Nimotuzumab
Giuseppe Tridente

29. Ofatumumab
Giuseppe Tridente

30. Omalizumab
Giuseppe Tridente

31. Palivizumab
Giuseppe Tridente

32. Panitumumab
Giuseppe Tridente

33. Pertuzumab
Giuseppe Tridente

34. Ranibizumab
Giuseppe Tridente

35. Rituximab
Giuseppe Tridente

36. Tocilizumab
Giuseppe Tridente

37. Tositumomab
Giuseppe Tridente

38. Trastuzumab
Giuseppe Tridente

39. Ustekinumab
Giuseppe Tridente

Part III. Fusion Proteins

40. Fusion Proteins
Giuseppe Tridente

41. Abatacept
Giuseppe Tridente

42. Aflibercept
Giuseppe Tridente

43. Alefacept
Giuseppe Tridente

44. Belatacept
Giuseppe Tridente

45. Etanercept
Giuseppe Tridente

46. Rilonacept
Giuseppe Tridente

47. Romiplostim
Giuseppe Tridente

Part IV. Cytokines

48. Cytokines
Giuseppe Tridente

49. Interleukins
Giuseppe Tridente

50. Denileukin-Diftitox
Giuseppe Tridente

51. Anakinra
Giuseppe Tridente

52. Interferons
Giuseppe Tridente

53. Hemopoietic Stimulatory Factors
Giuseppe Tridente

54. Myelopoietic Stimulatory Factors
Giuseppe Tridente

55. Thrombopoietic Stimulatory Factor
Giuseppe Tridente

56. Pluripotent Growth Factors
Giuseppe Tridente

57. Epidermal Growth Factors
Giuseppe Tridente

Part V. Overview

58. Biomedicines as Adverse Event Inducers
Giuseppe Tridente

59. Conclusions and Perspectives
Giuseppe Tridente

Avainsanat: Biomedicine, Biomedicine general, Medicine/Public Health, general, Pharmacy